Precipio Inc
NASDAQ:PRPO
Intrinsic Value
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. [ Read More ]
The intrinsic value of one PRPO stock under the Base Case scenario is 21.53 USD. Compared to the current market price of 6.15 USD, Precipio Inc is Undervalued by 71%.
Valuation Backtest
Precipio Inc
Run backtest to discover the historical profit from buying and selling PRPO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Precipio Inc
Current Assets | 3.7m |
Cash & Short-Term Investments | 1.5m |
Receivables | 1.3m |
Other Current Assets | 879k |
Non-Current Assets | 14.4m |
PP&E | 1.5m |
Intangibles | 12.8m |
Other Non-Current Assets | 76k |
Current Liabilities | 3.1m |
Accounts Payable | 622k |
Accrued Liabilities | 2m |
Other Current Liabilities | 477k |
Non-Current Liabilities | 531k |
Long-Term Debt | 124k |
Other Non-Current Liabilities | 407k |
Earnings Waterfall
Precipio Inc
Revenue
|
15.2m
USD
|
Cost of Revenue
|
-9.2m
USD
|
Gross Profit
|
6m
USD
|
Operating Expenses
|
-13.6m
USD
|
Operating Income
|
-7.6m
USD
|
Other Expenses
|
1.8m
USD
|
Net Income
|
-5.9m
USD
|
Free Cash Flow Analysis
Precipio Inc
PRPO Profitability Score
Profitability Due Diligence
Precipio Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Precipio Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
PRPO Solvency Score
Solvency Due Diligence
Precipio Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Precipio Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRPO Price Targets Summary
Precipio Inc
According to Wall Street analysts, the average 1-year price target for PRPO is 19 USD .
Ownership
PRPO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PRPO Price
Precipio Inc
Average Annual Return | -37.51% |
Standard Deviation of Annual Returns | 37.31% |
Max Drawdown | -97% |
Market Capitalization | 8.7m USD |
Shares Outstanding | 1 420 120 |
Percentage of Shares Shorted | 0.38% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in Omaha, Nebraska and currently employs 55 full-time employees. The company went IPO on 2000-07-18. The firm is focused on developing various technologies including IV-Cell, HemeScreen and ICE-COLD-PCR (ICP). The IV-Cell is a cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables culturing of all four hematopoietic cell lineages, which include myeloid cells, B-cells, T-cells and plasma cells. The diagnostic process of hematopoietic diseases involves chromosomal analysis by conducting cell-culture-based tests in a cytogenetics laboratory to imitate in-vivo conditions. HemeScreen technology was developed by the Company targeting Myeloproliferative Neoplasms (MPN), which has evolved into a suite of robust genetic diagnostic panels. ICP technology was developed at Harvard and is licensed exclusively by Dana-Farber. Its laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha.
Contact
IPO
Employees
Officers
The intrinsic value of one PRPO stock under the Base Case scenario is 21.53 USD.
Compared to the current market price of 6.15 USD, Precipio Inc is Undervalued by 71%.